EGFR and non-small cell lung carcinoma: Despite these limitations, to the best of our knowledge, RESET is the first multicenter study in South Korea based on real‐world experience, and its applicability to real clinical practice, especially for Asian populations, could allow better patient management and improved survival outcomes in patients with EGFR‐mutated advanced NSCLC.